Vestal Point Capital, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001974915

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 63 positions · Total reported value $3.87B · Top-10 concentration 67.3% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 14 new · 20 cut · 19 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.4% · vs SPY -15.5% · Prev Value $4.28B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -2.9% · vs SPY -5.1% · Latest Value $3.87B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Vestal Point Capital, LP disclosed 63 equity positions with a combined reported value of $3.87B. The filing implies a focused portfolio: its ten largest positions account for 67.3% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were ABVX ($392.12M), NBIX ($354.60M), BMRN ($331.50M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Vestal Point Capital, LP opened 14 new positions, trimmed 20 and fully exited 19, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 60% of names.

The largest new positions opened in Q3 2026 were TVTX ($35.33M), RCUS ($33.58M), BBIO ($26.32M).

Of the 19 positions fully exited versus the prior quarter, the largest were ABT ($127.04M), AZN ($85.33M), RVMD ($84.28M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • TVTX TRAVERE THERAPEUTICS INC · $35.33M
  • RCUS ARCUS BIOSCIENCES INC · $33.58M
  • BBIO BRIDGEBIO PHARMA INC · $26.32M
  • ZYME ZYMEWORKS INC · $15.89M
  • COGT COGENT BIOSCIENCES INC · $15.21M
  • STOK STOKE THERAPEUTICS INC · $8.97M
  • ANIX ANIXA BIOSCIENCES INC · $8.42M
  • GKOS GLAUKOS CORP · $7.39M

Fully Exited (vs previous quarter)

  • ABT ABBOTT LABORATORIES · prev qtr: $127.04M
  • AZN ASTRAZENECA PLC · prev qtr: $85.33M
  • RVMD REVOLUTION MEDICINES INC · prev qtr: $84.28M
  • BCRX BIOCRYST PHARMACEUTICALS INC · prev qtr: $83.00M
  • RGEN REPLIGEN CORP · prev qtr: $54.58M
  • BMY BRISTOL-MYERS SQUIBB CO · prev qtr: $46.10M
  • QURE UNIQURE NV · prev qtr: $43.07M
  • MDGL MADRIGAL PHARMACEUTICALS INC · prev qtr: $34.90M

Insider Transactions (Form 4)

Latest Vestal Point Capital, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Vestal Point Capital, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 63 US equity positions with a combined value of $3.87B. HoldingsHub carries 12 quarters of its filings (Q4 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-127682 (status: Approved), registered 2023-04-14
  • Regulatory AUM (Form ADV): $5.47B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds
  • Website: vestalpoint.com

Portfolio Structure

  • 63 positions · $3.87B reported value (Q3 2026)
  • Top 10 holdings = 67.3% of reported value
  • Largest position: ABVX (ABIVAX SA) at 10.1%
  • Average position size: $61.44M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 14 new, 22 added, 20 reduced, 19 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: Aggressive growth tilt, particularly in biotech/Health Care, with significant new positions and share increases, suggesting high conviction in clinical-stage drug developers. 2. Key moves: Added 14 new positions (including ARWR, INSM, TARS with >90% share increases); reduced BMRN, NRIX, ELVN (-8.3% to -19.4% QoQ). 3. Portfolio structure: Active, concentrated (63 positions), heavily Health Care-focused (100% of top 10), high-risk appetite (small/mid-cap biotech dominance). 4. Per-holding one-liner: - ABVX: Abivax SA (HIV/hepatitis B, unverified) - NBIX: Neurocrine Biosciences (neurology, unverified) - BMRN: BioMarin Pharmaceutical (genetic diseases, unverified) - ARWR: Arrowhead Pharmaceuticals (RNA therapeutics, unverified) - INSM: Insmed Inc (rare lung diseases, unverified) - UTHR: United Therapeutics (pulmonary hypertension, unverified) - ASND: Ascendis Pharma A/S (growth disorders, unverified) - NRIX: Nurix Therapeutics (targeted protein degradation, unverified) - TARS: Tarsus Pharmaceuticals (eye disease, unverified) - ELVN: Enliven Therapeutics (Parkinson’s, unverified) 5. Style summary: Concentrated, high-conviction biotech fund with aggressive new bets and selective trims.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 09:48

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 3.96M $392.12M 10.13%
10.13%
Add
2 2.50M $354.60M 9.16%
9.16%
Add
3 5.53M $331.50M 8.56%
8.56%
Reduce
4 4.82M $315.14M 8.14%
8.14%
Add
5 2.73M $311.03M 8.04%
8.04%
Add
6 475.00K $257.40M 6.65%
6.65%
Add
7 740.00K $168.59M 4.36%
4.36%
Add
8 7.03M $166.56M 4.30%
4.30%
Reduce
9 2.03M $159.86M 4.13%
4.13%
Add
10 3.23M $147.83M 3.82%
3.82%
Reduce
11 1.64M $107.03M 2.77%
2.77%
Add
12 5.53M $102.82M 2.66%
2.66%
Add
13 6.20M $99.88M 2.58%
2.58%
Add
14 11.20M $98.34M 2.54%
2.54%
Add
15 18.05M $87.88M 2.27%
2.27%
Reduce
16 7.13M $85.06M 2.20%
2.20%
Add
17 915.00K $68.53M 1.77%
1.77%
Add
18 3.00M $43.77M 1.13%
1.13%
Add
19 475.00K $42.19M 1.09%
1.09%
Reduce
20 600.00K $35.33M 0.91%
0.91%
New
21 1.30M $33.58M 0.87%
0.87%
New
22 850.00K $31.61M 0.82%
0.82%
Add
23 510.00K $30.88M 0.80%
0.80%
Reduce
24 545.00K $27.15M 0.70%
0.70%
Hold
25 400.00K $26.32M 0.68%
0.68%
New
26 850.00K $25.75M 0.67%
0.67%
Reduce
27 175.00K $22.83M 0.59%
0.59%
Reduce
28 1.50M $21.41M 0.55%
0.55%
Reduce
29 500.00K $20.61M 0.53%
0.53%
Reduce
30 3.30M $17.03M 0.44%
0.44%
Add
31 640.00K $16.64M 0.43%
0.43%
Reduce
32 600.00K $15.89M 0.41%
0.41%
New
33 475.00K $15.21M 0.39%
0.39%
New
34 2.08M $15.07M 0.39%
0.39%
Reduce
35 4.32M $14.60M 0.38%
0.38%
Hold
36 800.00K $12.26M 0.32%
0.32%
Add
37 395.00K $10.65M 0.28%
0.28%
Add
38 1.25M $10.32M 0.27%
0.27%
Add
39 290.00K $9.45M 0.24%
0.24%
Reduce
40 345.00K $8.97M 0.23%
0.23%
New
41 263.11K $8.42M 0.22%
0.22%
New
42 395.00K $8.41M 0.22%
0.22%
Reduce
43 360.00K $8.38M 0.22%
0.22%
Reduce
44 1.86M $7.74M 0.20%
0.20%
Add
45 45.00K $7.39M 0.19%
0.19%
New
46 625.00K $7.14M 0.18%
0.18%
Add
47 850.00K $6.60M 0.17%
0.17%
Reduce
48 525.00K $6.14M 0.16%
0.16%
New
49 1.46M $6.02M 0.16%
0.16%
Add
50 169.74K $6.02M 0.15%
0.15%
Reduce

FAQ

What did Vestal Point Capital, LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Vestal Point Capital, LP reported 63 equity positions worth $3.87B in aggregate; its largest disclosed positions were ABVX ($392.12M), NBIX ($354.60M), BMRN ($331.50M).

How large is Vestal Point Capital, LP's portfolio?

Vestal Point Capital, LP reported $3.87B of long equity holdings across 63 positions as of 2026-Q3. Top-10 holdings account for 67.3% of reported value.

What is Vestal Point Capital, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/vestal-point-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →